Baselga J, Dent SF, Cortés J, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. ASCO 2018. J Clin Oncol 36, 2018 (suppl; abstr LBA1006).
Argininedeprivatie bij ASS1-deficient maligne pleuraal mesothelioom
jan 2017 | Mesothelioom